1. Home
  2. WIX vs NUVL Comparison

WIX vs NUVL Comparison

Compare WIX & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wix.com Ltd.

WIX

Wix.com Ltd.

HOLD

Current Price

$106.38

Market Cap

7.6B

Sector

Technology

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$101.62

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIX
NUVL
Founded
2006
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
7.1B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
WIX
NUVL
Price
$106.38
$101.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
21
14
Target Price
$184.00
$134.29
AVG Volume (30 Days)
1.9M
711.2K
Earning Date
11-19-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
47.59
N/A
EPS
2.36
N/A
Revenue
$1,929,230,000.00
N/A
Revenue This Year
$14.50
N/A
Revenue Next Year
$14.24
N/A
P/E Ratio
$44.11
N/A
Revenue Growth
13.22
N/A
52 Week Low
$92.23
$55.54
52 Week High
$247.11
$112.88

Technical Indicators

Market Signals
Indicator
WIX
NUVL
Relative Strength Index (RSI) 46.56 47.10
Support Level $97.12 $103.52
Resistance Level $108.70 $107.99
Average True Range (ATR) 4.71 3.14
MACD 1.99 -1.21
Stochastic Oscillator 82.10 13.02

Price Performance

Historical Comparison
WIX
NUVL

About WIX Wix.com Ltd.

Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: